- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: Dna Probe.
Displaying page 1 of 1.
EudraCT Number: 2011-005219-98 | Sponsor Protocol Number: PH3-01 | Start Date*: 2012-10-08 | |||||||||||
Sponsor Name:Galena Biopharma, Inc | |||||||||||||
Full Title: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT) | |||||||||||||
Medical condition: Operable early-stage, node-positive breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004305-40 | Sponsor Protocol Number: CSL222-3001 | Start Date*: 2018-10-12 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene ... | |||||||||||||
Medical condition: Hemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Ongoing) GB (GB - no longer in EU/EEA) IE (Restarted) NL (Ongoing) DE (Restarted) BE (Ongoing) SE (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001883-23 | Sponsor Protocol Number: 2011CV08 | Start Date*: 2011-08-03 | |||||||||||
Sponsor Name:University of Dundee | |||||||||||||
Full Title: FAST- Febuxostat versus Allopurinol Streamlined Trial A prospective, randomised, open-label, blinded endpoint (PROBE) clinical trial evaluating long term cardiovascular safety of febuxostat in co... | |||||||||||||
Medical condition: Chronic symptomatic hyperuricaemic | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DK (Completed) FI (Prematurely Ended) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020069-26 | Sponsor Protocol Number: DMD114044 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development LTD | |||||||||||||
Full Title: A phase III, randomized, double blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in subjects with Duchenne muscular dystrophy. | |||||||||||||
Medical condition: Duchenne muscular dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) IT (Completed) PL (Completed) CZ (Completed) ES (Completed) NO (Completed) DK (Completed) HU (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024566-22 | Sponsor Protocol Number: DMD114118 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development LTD | |||||||||||||
Full Title: A double-blind, escalating dose, randomized, placebo-controlled study to assess the pharmacokinetics, safety and tolerability of single subcutaneous injections of GSK2402968 in non-ambulant subject... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003213-18 | Sponsor Protocol Number: RHMCAN1129 | Start Date*: 2017-01-13 | |||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
Full Title: A Phase Ib/II combination trial of acalabrutinib with rituximab, cyclophosphamide, doxorubicin,vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL) | |||||||||||||
Medical condition: Diffuse large B-cell lymphomas (most common type of non-Hodgkins lymphoma) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019237-10 | Sponsor Protocol Number: FARM8MR2J7 | Start Date*: 2010-10-28 | |||||||||||
Sponsor Name:ISTITUTO GIANNINA GASLINI | |||||||||||||
Full Title: Multicenter prospective randomized open with a blinded end point (PROBE) parallel-group study on treatment with biphasic insulin BIAsp70/30 and short-acting insulin or rapid-acting analogue plus gl... | |||||||||||||
Medical condition: DM1 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002913-12 | Sponsor Protocol Number: M12-895 | Start Date*: 2012-05-15 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplati... | |||||||||||||
Medical condition: BRCA1 or BRCA2 mutation metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) DK (Completed) SK (Completed) FI (Completed) SE (Completed) BE (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018412-32 | Sponsor Protocol Number: DMD114117 | Start Date*: 2010-08-05 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development LTD | |||||||||||||
Full Title: A phase II, double blind, exploratory, parallel-group, placebo-controlled clinical study to assess two dosing regimens of GSK2402968 for efficacy, safety, tolerability and pharmacokinetics in ambul... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (Completed) NL (Completed) FR (Completed) ES (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005437-53 | Sponsor Protocol Number: ITCC053 | Start Date*: 2016-11-03 |
Sponsor Name:Erasmus Medical Center | ||
Full Title: A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies Study ITCC 053 | ||
Medical condition: Malignancies carrying a genetic alteration of ALK, MET or ROS1 | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) DE (Ongoing) IE (Completed) ES (Ongoing) DK (Trial now transitioned) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005040-10 | Sponsor Protocol Number: PRO045-CLIN-01 | Start Date*: 2012-12-03 | |||||||||||
Sponsor Name:BioMarin Nederland B.V. | |||||||||||||
Full Title: A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple subcutaneous doses of PRO045 in subjects with Duchenne muscular dystrophy | |||||||||||||
Medical condition: Duchenne muscular dystrophy resulting from a mutation correctable by PRO045-induced DMD exon 45 skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) IT (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-005027-16 | Sponsor Protocol Number: NOA-18 | Start Date*: 2020-09-16 | ||||||||||||||||
Sponsor Name:Ruprecht-Karls University Heidelberg Medical Faculty, represented by Heidelberg University Hospital | ||||||||||||||||||
Full Title: Improvement of functional Outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial | ||||||||||||||||||
Medical condition: WHO grade II or III glioma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005042-35 | Sponsor Protocol Number: PRO053-CLIN-01 | Start Date*: 2013-08-23 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
Full Title: A Phase I/II, open-label, dose escalating with 48 week treatment study to assess the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of BMN 053 (previously known as PRO053)... | |||||||||||||
Medical condition: Duchenne muscular dystrophy resulting from a mutation correctable by BMN 053-induced DMD exon 53 skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) BE (Completed) IT (Prematurely Ended) NL (Prematurely Ended) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000844-25 | Sponsor Protocol Number: R668-EE-1774 | Start Date*: 2019-10-21 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (EoE) | |||||||||||||
Medical condition: Eosinophilic Esophagitis (EoE) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Ongoing) SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PT (Completed) BE (Completed) IT (Completed) ES (Restarted) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005537-35 | Sponsor Protocol Number: E5564-G000-301 | Start Date*: 2006-08-30 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis | |||||||||||||
Medical condition: Severe Sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) AT (Completed) CZ (Completed) ES (Completed) DE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003170-27 | Sponsor Protocol Number: GEICAM/2013-02 | Start Date*: 2013-11-21 | |||||||||||
Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama) | |||||||||||||
Full Title: Phase III study of Palbociclib (PD-0332991) in combination with Exemestane versus chemotherapy (capecitabine) in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patient... | |||||||||||||
Medical condition: Patients with hormonal receptor positive and HER2 negative MBC who are resistant to prior NSAI therapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) AT (Completed) HU (Completed) LV (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001691-41 | Sponsor Protocol Number: EMN29 | Start Date*: 2021-12-28 | |||||||||||
Sponsor Name:European Myeloma Network | |||||||||||||
Full Title: A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPL... | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) GR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004455-36 | Sponsor Protocol Number: NP28673 | Start Date*: 2013-04-11 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd | |||||||||||||
Full Title: AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER PHASE I/II TRIAL OF RO5424802 GIVEN ORALLY TO NON - SMALL CELL LUNG CANCER PATIENTS WHO HAVE ALK MUTATION AND FAILED CRIZOTINIB TREATMENT | |||||||||||||
Medical condition: ALK-mutated Non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed) NL (Completed) BE (Completed) FR (Completed) DK (Completed) LU (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.